Glycine, B6, and Other Additives in Compounded GLP-1s: The Evidence Review

Your compounded semaglutide vial may contain more than just semaglutide and bacteriostatic water. Some compounding pharmacies add ingredients — glycine, vitamin B6, vitamin B12, L-carnitine, or other compounds — to their GLP-1 formulations, marketed as enhancing effectiveness, reducing side effects, or supporting overall metabolic health. The question is whether these additives do what they claim.

Cyanocobalamin (Vitamin B12)

B12 is the most common additive in compounded GLP-1 formulations, and it has the strongest rationale. Semaglutide and other GLP-1 receptor agonists slow gastric emptying and reduce food intake — two effects that can contribute to micronutrient deficiencies over time. B12 deficiency specifically has been documented in long-term GLP-1 users, likely due to reduced absorption from decreased gastric acid production and slower intestinal transit.

The evidence: B12 deficiency is a recognized concern during extended GLP-1 therapy. The Endocrine Society recommends monitoring B12 levels in patients on long-term GLP-1 treatment. Adding B12 to the formulation provides a safeguard against deficiency without requiring a separate supplement.

The verdict: B12 supplementation has a legitimate clinical rationale for GLP-1 patients. Including it in the formulation is convenient and evidence-supported, though oral B12 supplements achieve the same goal.

Glycine

Glycine is an amino acid included in some compounded semaglutide formulations. It serves dual purposes: as a formulation stabilizer (helping maintain peptide stability in solution) and as a purported metabolic support ingredient.

The formulation rationale: Glycine can act as a buffering agent and cryoprotectant in peptide formulations, helping maintain pH and protecting the peptide during freeze-thaw cycles. This is a legitimate pharmaceutical excipient use — glycine is used in numerous FDA-approved injectable products for the same purpose.

The clinical rationale: Some providers market glycine as supporting sleep quality, blood sugar regulation, or anti-inflammatory effects. While glycine research exists in each of these areas, the doses studied are typically 3-5 grams orally — orders of magnitude larger than the milligram quantities present in a compounded GLP-1 injection. The amount of glycine in a typical GLP-1 formulation is pharmacologically insignificant for these purposes.

The verdict: As a formulation stabilizer, glycine is a reasonable excipient choice. As a clinical add-on marketed for metabolic benefits, the doses involved are too small to produce the claimed effects.

Pyridoxine (Vitamin B6)

B6 appears in some compounded GLP-1 formulations, marketed for nausea reduction and metabolic support.

The evidence: Vitamin B6 has established antiemetic properties — it's a first-line treatment for pregnancy-related nausea (often combined with doxylamine as Diclegis/Bonjesta). Whether B6 reduces GLP-1-induced nausea specifically has not been studied in controlled trials. The mechanism is plausible (B6 affects serotonin metabolism, which is involved in nausea pathways), but the evidence is extrapolated rather than direct.

The verdict: The antiemetic rationale has pharmacological plausibility but no GLP-1-specific data. If B6 were effective at reducing GLP-1 nausea, it would be a meaningful clinical benefit. But "plausible" is not "proven," and patients should not choose a formulation solely based on the B6 add-on.

L-Carnitine

L-carnitine is an amino acid derivative involved in fatty acid transport into mitochondria. Some providers include it in GLP-1 formulations or offer it as a separate injectable, marketed for fat metabolism enhancement and energy production.

The evidence: L-carnitine supplementation has been studied for weight management, exercise performance, and metabolic health. Systematic reviews have found modest effects on weight loss (roughly 1-2 kg more than placebo) in some populations, but results are inconsistent. There are no studies examining L-carnitine's effects specifically in combination with GLP-1 agonists.

The verdict: The evidence for L-carnitine as a standalone weight management supplement is weak. As an add-on to GLP-1 therapy, there is no specific evidence supporting synergistic benefits. It's not harmful at standard supplementation doses, but marketing it as enhancing GLP-1 effectiveness overstates the evidence.

When Add-Ons Are Marketing

The business incentive to add ingredients is straightforward: a "semaglutide + B12 + B6 + glycine formula" sounds more premium than "semaglutide in bacteriostatic water." The additional ingredient costs are negligible — pennies per vial — but they justify higher pricing and differentiate the pharmacy's product from competitors.

This isn't necessarily deceptive. B12 inclusion is genuinely useful. Glycine as a stabilizer is good pharmaceutical practice. But patients should evaluate these formulations based on the evidence for each ingredient rather than assuming that more ingredients equals better medication.

Providers With Evidence-Based Formulations